Xenon Pharmaceuticals Showcases XEN1101 Epilepsy Program at 35th International Epilepsy Congress
New interim data from ongoing Phase 2b X-TOLE open-label extension demonstrates improvement in overall quality-of-life when compared to baseline Clinically important improvements seen for all...
British Columbia United Kingdom Jodi Regts Christopher Kenney Ian Mortimer Xenon Pharmaceuticals Inc
Source: marketscreener.com